Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults

Clinical trial NCT05210413 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05210413
Sponsor: University Hospital, Bordeaux
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Refractory or Recurrent Solid Tumor

Start date: 2022-05-17
Primary completion: 2025-08-26
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.